The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Open accessAbstract
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS: We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes. RESULTS: Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06). CONCLUSIONS: Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although our analysis is secondary, reanalyses of clinical trial data have led to the detection of adverse events well after the market entry of major drugs such as rofecoxib and rosiglitazone. [36,37]”
From Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults (2022) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In one study, 9 the use of rosiglitazone decreased the risk of diabetes in adults with impaired glucose tolerance by 62%; given concerns about cardiovascular safety, 14 however, the Food and Drug Administration has restricted the use of rosig litazone therapy to patients in whom glycemic control cannot be achieved with other medications and who cannot take pioglitazone.”
From Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“a well-publicized meta-analysis of small phase 3 trials suggesting an increase in myocardial ischemic events (odds ratio, 1.43 [95% CI, 1.03–1.98])”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [210]
In the citing paper
“Several meta-analyses have suggested a 30–40% relative increase in risk for myocardial infarction (65,66) with rosiglitazone.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 552
Self-citationEffect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
Fonseca, V. A., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 538
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.86.1.280 · DOI
Cited by
Sorted by citations
Items 201–300 of 1,024
Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.036 · Cited by 228
“[36,37] Our analysis has an advantage over postmarketing observational studies in that the data are from blinded, placebo-controlled randomized trials vetted by the FDA, which were matched against a list of adverse events created before the availability of the clinical-trial results and designed…”
MethodObesity and Polycystic Ovary Syndrome
Vrbíková, J., & Hainer, V. (2009) · Obesity Facts · doi:10.1159/000194971 · Cited by 244
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Zelniker, T. A., & Braunwald, E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.040 · Cited by 236
Current and Emerging Drug Treatment Options for Alzheimerʼs Disease
Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 245
ACOG Practice Bulletin No. 194: polycystic ovary syndrome
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002656 · Cited by 231
pre-diabetes Task Force on diabetes (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 239
Lo, B. (2015) · JAMA · doi:10.1001/jama.2015.292 · Cited by 235
Practical guide to the meta-analysis of rare events
Efthimiou, O. (2018) · Evidence Based Mental Health · doi:10.1136/eb-2018-102911 · Cited by 231
Review article: Coagulation and fibrinolysis in diabetes
Alzahrani, S. H., & Ajjan, R. (2010) · Diabetes and Vascular Disease Research · doi:10.1177/1479164110383723 · Cited by 234
Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial
Lewis, J. D., Lichtenstein, G. R., Deren, J. J., Sands, B. E., Hanauer, S. B., Katz, J. A., Lashner, B. A., Present, D. H., Chuai, S., Ellenberg, J. H., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.012 · Cited by 229
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 231
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Eichler, H., Pignatti, F., Flamion, B., Leufkens, H. G. M., & Breckenridge, A. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2664 · Cited by 235
Ceolotto, G., Gallo, A., Papparella, I., Franco, L., Murphy, E. G., Iori, E., Pagnin, E., Fadini, G. P., Albiero, M., Semplicini, A., et al. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.155762 · Cited by 230
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Meta‐research: The art of getting it wrong
Ioannidis, J. P. A. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.19 · Cited by 237
Drug safety assessment in clinical trials: methodological challenges and opportunities
Singh, S., & Loke, Y. K. (2012) · Trials · doi:10.1186/1745-6215-13-138 · Cited by 237
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60794-7 · Cited by 227
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
Dormandy, J., Bhattacharya, M., & van Troostenburg, A. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227
Norris, S. L., Kansagara, D. L., Bougatsos, C., & Fu, R. F. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00008 · Cited by 226
Berberine in the treatment of type 2 diabetes mellitus: A systemic review and meta-analysis
Dong, H., Wang, N., Zhao, L., & Lu, F. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/591654 · Cited by 225
Atherosclerosis – A matter of unresolved inflammation
Viola, J. R., & Soehnlein, O. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.013 · Cited by 229
National Trends in Treatment of Type 2 Diabetes Mellitus, 1994-2007
Alexander, G. C., Sehgal, N. L., Moloney, R., & Stafford, R. S. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2088 · Cited by 225
Tissue Factor, Blood Coagulation, and Beyond: An Overview
Chu, A. J. (2011) · International Journal of Inflammation · doi:10.4061/2011/367284 · Cited by 226
Gustafsson, L. L., Wettermark, B., Godman, B., Karlsson, E., Bergman, U., Hasselström, J., Hensjö, L., Hjemdahl, P., Jägre, I., Julander, M., et al. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00682.x · Cited by 227
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.04.001 · Cited by 222
Johansen, O. E., Neubacher, D., von Eynatten, M., Patel, S. D., & Woerle, H. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-3 · Cited by 219
Adipose Inflammation, Insulin Resistance, and Cardiovascular Disease
Shah, A. D., Mehta, N. N., & Reilly, M. P. (2008) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607108325251 · Cited by 218
Recent advances in nonalcoholic fatty liver disease
Cheung, O., & Sanyal, A. J. (2009) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3283294a18 · Cited by 217
Top‐down proteomics in health and disease: Challenges and opportunities
Gregorich, Z. R., & Ge, Y. (2014) · PROTEOMICS · doi:10.1002/pmic.201300432 · Cited by 217
Angiotensin II AT1 receptor blockers as treatments for inflammatory brain disorders
Saavedra, J. M. (2012) · Clinical Science · doi:10.1042/cs20120078 · Cited by 221
Frederich, R. C., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R. K., Wolf, R., & Mahaffey, K. W. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2138 · Cited by 216
Role of AMP‐activated protein kinase in the metabolic syndrome and in heart disease
Hardie, D. G. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.11.018 · Cited by 221
Appetite regulation and weight control: the role of gut hormones
Perry, B., & Wang, Y. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2011.21 · Cited by 229
Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
Lee, K., Bacchetti, P., & Sim, I. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050191 · Cited by 215
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
Rosak, C., & Mertes (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s28340 · Cited by 221
Adipocytokines in relation to cardiovascular disease
de Voorde, J. V., Pauwels, B., Boydens, C., & Decaluwé, K. (2013) · Metabolism · doi:10.1016/j.metabol.2013.06.004 · Cited by 215
Gaziano, J. M., Cincotta, A. H., O’Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 214
Use of Antidiabetic Drugs in the U.S., 2003–2012
Hampp, C., Borders‐Hemphill, V., Moeny, D. G., & Wysowski, D. K. (2014) · Diabetes Care · doi:10.2337/dc13-2289 · Cited by 214
Zhou, J., Zhou, S., Tang, J., Zhang, K., Guang, L.-X., Huang, Y., Xu, Y. X., Ying, Y., Zhang, L., & Li, D. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.12.056 · Cited by 208
Hollander, P. A., Li, J., Allen, E., Chen, R. K., & for the CV181-013 Investigators (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0550 · Cited by 206
PPARs and the Cardiovascular System
Hamblin, M., Chang, L., Fan, Y., Zhang, J., & Chen, Y. E. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2280 · Cited by 210
Rao, A. D., Kuhadiya, N. D., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Luo, H., Chen, J., Shi, L., Mikailov, M., Zhu, H., Wang, K., He, L., & Yang, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr299 · Cited by 206
Henry, R. R., Lincoff, A. M., Mudaliar, S. R. D., Rabbia, M. A., Chognot, C., & Herz, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60870-9 · Cited by 208
The Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting
Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 201
The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1309610 · Cited by 204
Ziouzenkova, O., & Plutzky, J. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.11.081 · Cited by 202
Hernández, A. V., Usmani, A., Rajamanickam, A., & Moheet, A. A. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11587580-000000000-00000 · Cited by 203
Hypertriglyceridemia secondary to obesity and diabetes
Subramanian, S., & Chait, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.003 · Cited by 205
Insulin Resistance and Atherosclerosis
Razani, B., Chakravarthy, M. V., & Semenkovich, C. F. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.05.001 · Cited by 201
Nathan, D. M. (2009) · Diabetes Care · doi:10.2337/dc09-0271 · Cited by 207
Mannucci, E., Monami, M., Lamanna, C., Gori, F., & Marchionni, N. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.021 · Cited by 199
Tardif, J., McMurray, J. J. V., Klug, E., Small, R., Schumi, J., Choi, J., Cooper, J., Scott, R. C., Lewis, E. F., L’Allier, P. L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60763-1 · Cited by 204
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
Skeletal consequences of thiazolidinedione therapy
Grey, A. B. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0477-y · Cited by 198
Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis
Sarafidis, P. A., Stafylas, P. C., Georgianos, P. I., Saratzis, A. N., & Lasaridis, A. N. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.11.013 · Cited by 197
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Sheahan, K. H., Wahlberg, E. A., & Gilbert, M. P. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137186 · Cited by 194
Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., & Kawamori, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0222 · Cited by 197
Brocq, M. L. L., Leslie, S. J., Milliken, P. H., & Megson, I. L. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.2013 · Cited by 196
Bolli, G. B., Dotta, F., Rochotte, E., & Cohen, S. E. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00820.x · Cited by 192
Obesity, Inflammation, and the Potential Application of Pharmaconutrition
Cave, M. C., Hurt, R. T., Frazier, T. H., Matheson, P. J., Garrison, R. N., McClain, C. J., & McClave, S. A. (2008) · Nutrition in Clinical Practice · doi:10.1177/011542650802300116 · Cited by 192
Schreuder, T. C. M. A., Verwer, B. J., van Nieuwkerk, C. M., & Mulder, C. J. J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2474 · Cited by 197
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Jiang, K., Xu, Y., Wang, D., Chen, F., Tu, Z., Qian, J., Xu, S., Xu, Y., Hwa, J., Li, J., et al. (2021) · Protein & Cell · doi:10.1007/s13238-020-00809-4 · Cited by 200
Yudkin, J. S., Lipska, K. J., & Montori, V. M. (2011) · BMJ · doi:10.1136/bmj.d7995 · Cited by 189
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Talha, K. M., Anker, S. D., & Butler, J. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0030 · Cited by 209
New Drugs for the Treatment of Diabetes
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 188
The renin–angiotensin–aldosterone system and glucose homeostasis
Luther, J. M., & Brown, N. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.006 · Cited by 185
Vijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185
Effect of pioglitazone medication on the incidence of dementia
Heneka, M. T., Fink, A., & Doblhammer, G. (2015) · Annals of Neurology · doi:10.1002/ana.24439 · Cited by 187
Lorenzati, B., Zucco, C., Miglietta, S., Lamberti, F., & Bruno, G. (2010) · Pharmaceuticals · doi:10.3390/ph3093005 · Cited by 194
Mellbin, L., Malmberg, K., Norhammar, A., Wedel, H., Rydén, L., & for the DIGAMI 2 Investigators (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm518 · Cited by 184
U.S. Preventive Services Task Force* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-11-200806030-00007 · Cited by 185
Dagenais (2008) · doi:10.2337/dc07-1868 · Cited by 183
Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
Lecka‐Czernik, B. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0027-y · Cited by 187
Moving Toward Transparency of Clinical Trials
Zarin, D. A., & Tse, T. (2008) · Science · doi:10.1126/science.1153632 · Cited by 185
Rosiglitazone and Cardiovascular Risk
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078099 · Cited by 179
I Diretriz Brasileira de Prevenção Cardiovascular
Simão, A., Précoma, D., Andrade, J., Filho, H. C., Saraiva, J., Oliveira, G., Murro, A., Campos, A., Alessi, A., Avezum, Á., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s012 · Cited by 186
New developments in the medical treatment of endometriosis
Bedaiwy, M. A., Alfaraj, S., Yong, P., & Casper, R. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.025 · Cited by 176
Macrophage PPARγ and impaired wound healing in type 2 diabetes
Mirza, R. E., Fang, M. M., Novak, M. L., Urao, N., Sui, A., Ennis, W. J., & Koh, T. J. (2015) · The Journal of Pathology · doi:10.1002/path.4548 · Cited by 177
“Since there is uncertainty about the effects of PPARγ agonists on the risk of cardiovascular events in humans [57,58], our data are important because they demonstrate that topical administration of PPARγ agonists down-regulated inflammation and improved angiogenesis, granulation tissue formation and wound closure.”
BackgroundGlycemic Management of Type 2 Diabetes Mellitus
Ismail‐Beigi, F. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1013127 · Cited by 186
Lee, M.-W., Lee, M., & Oh, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060854 · Cited by 192
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 177
Drug-Review Deadlines and Safety Problems
Carpenter, D. P., Zucker, E. J., & Avorn, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0706341 · Cited by 175
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
Waugh, N., Cummins, E., Royle, P., Clar, C., Marien, M., Richter, B., & Philip, S. (2010) · Health Technology Assessment · doi:10.3310/hta14360 · Cited by 178
Therapeutic targets for treating fibrotic kidney diseases
Lee, S.-Y., Kim, S.-I., & Choi, M. E. (2014) · Translational research · doi:10.1016/j.trsl.2014.07.010 · Cited by 178
The Role of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) in Alzheimer’s Disease
Jiang, Q., Heneka, M. T., & Landreth, G. E. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00001 · Cited by 176
Pharmacogenetics in drug discovery and development: a translational perspective
Roses, A. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2593 · Cited by 177
Cardiovascular disease and modifiable cardiometabolic risk factors
Cannon, C. P. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80025-1 · Cited by 178
Feature selection and classification model construction on type 2 diabetic patients’ data
Huang, Y., McCullagh, P. J., Black, N. D., & Harper, R. (2007) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2007.07.002 · Cited by 174
Morrow, D. A., Scirica, B. M., Chaitman, B. R., McGuire, D. K., Murphy, S. A., Karwatowska-Prokopczuk, E., McCabe, C. H., & Braunwald, E. (2009) · Circulation · doi:10.1161/circulationaha.107.763912 · Cited by 170
Effects of diabetes drugs on the skeleton
Meier, C., Schwartz, A. V., Egger, A., & Lecka‐Czernik, B. (2015) · Bone · doi:10.1016/j.bone.2015.04.026 · Cited by 174
Wang, A. T., McCoy, C. P., Murad, M. H., & Montori, V. M. (2010) · BMJ · doi:10.1136/bmj.c1344 · Cited by 174
Visceral obesity and the heart
Mathieu, P., Pîbarot, P., Larose, É., Poirier, P., Marette, A., & Després, J. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.12.001 · Cited by 173
Patorno, E., Goldfine, A. B., Schneeweiß, S., Everett, B. M., Glynn, R. J., Liu, J., & Kim, S. C. (2018) · BMJ · doi:10.1136/bmj.k119 · Cited by 174
Covalent Peroxisome Proliferator-activated Receptor γ Adduction by Nitro-fatty Acids
Schopfer, F. J., Cole, M. P., Groeger, A. L., Chen, C.-S., Khoo, N. K. H., Woodcock, S. R., Golin-Bisello, F., Motanya, U. N., Li, Y., Zhang, J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091512 · Cited by 171
Minireview: Challenges and Opportunities in Development of PPAR Agonists
Wright, M. B., Bortolini, M., Tadayyon, M., & Bopst, M. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1427 · Cited by 172
Metadata
- Authors
- Nissen, S. E., & Wolski, K.
- Affiliations
- Cleveland Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-14
- Volume
- 356
- Issue
- 24
- Pages
- 2457-2471
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127125241
- Semantic Scholar
- 238422dc26dc6a78cb2b03fad835d7d1f1f95edb
- Cited by
- 4,675
- References
- 29
- Citations by year
- 2026: 62 · 2025: 66 · 2024: 89 · 2023: 117 · 2022: 132 · 2021: 169 · 2020: 175 · 2019: 198 · 2018: 213 · 2017: 222 · 2016: 234 · 2015: 218 · 2014: 259 · 2013: 271 · 2012: 295
- FWCI
- 395.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- New England Journal of Medicine (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, myocardial infarction, cardiovascular mortality, type 2 diabetes, thiazolidinediones, drug safety, HbA1c
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Middle Aged, Myocardial Infarction, Odds Ratio, Randomized Controlled Trials as Topic, Risk Assessment, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
